glp-1 and protein Glucagon-like Peptide-1 Receptor (GLP-1R) Signaling: Making the Case for a Functionally Gs Protein-Selective GPCR PDB-101: Molecule of the Month:

EPO-Fc, methoxy polyethylene glycol-epoetin beta (CERA)] EPO-mimetic agents and their constructs (e.g

The trial enrolled 307 participants without diabetes, with a placebo group achieving approximately 2.4% mean weight loss

It is not an exaggeration to say entire industries have been built on the back of the obesity epidemic, its drivers and its consequences

Although nearly all users may experience gastrointestinal side effects, such as nausea, vomiting, and diarrhea, these effects are usually manageable

Their mechanisms and evidence bases differ significantly

Recent Developments: In June 2025, Eli Lilly and Company entered a high-value partnership with Camurus to develop long-acting GLP-1 and dual/triple incretin therapies using Camurus proprietary FluidCrystal technology, with deal terms that could reach up to $870 million